BIRG:EURONEXT DUBLINBank of Ireland Group PLC Analysis
Data as of 2026-03-10 - not real-time
€15.99
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
The stock is trading just above its 20‑day simple moving average, while the 50‑day average remains a touch higher, indicating a tight range. RSI hovers around the midpoint, suggesting neither overbought nor oversold pressure. The MACD histogram sits in negative territory with the signal line above the MACD line, pointing to a modest bearish bias. Volatility over the past month is elevated, yet the beta is well below one, reflecting limited sensitivity to broader market moves. Market sentiment is in the “extreme greed” zone, which could be fueling short‑term buying pressure. Trading volume is on an upward trend, supporting liquidity.
On the valuation side, the price‑to‑earnings multiple trails the industry average, while the price‑to‑book ratio is modestly above one, hinting at a discount relative to peers. A dividend yield in the high single digits, coupled with a payout ratio under half, underscores strong cash return potential. The balance sheet shows ample cash against debt, and the debt‑to‑equity metric is effectively zero, indicating a solid capital position. Forward earnings estimates suggest a notable upside, and analyst consensus leans toward a buy with a target price well above the current level. The combination of a supportive dividend, attractive valuation, and improving earnings outlook makes the stock appealing for income‑focused investors. However, regulatory headwinds in the banking sector and the recent exit from a U.S. leveraged finance line warrant monitoring.
On the valuation side, the price‑to‑earnings multiple trails the industry average, while the price‑to‑book ratio is modestly above one, hinting at a discount relative to peers. A dividend yield in the high single digits, coupled with a payout ratio under half, underscores strong cash return potential. The balance sheet shows ample cash against debt, and the debt‑to‑equity metric is effectively zero, indicating a solid capital position. Forward earnings estimates suggest a notable upside, and analyst consensus leans toward a buy with a target price well above the current level. The combination of a supportive dividend, attractive valuation, and improving earnings outlook makes the stock appealing for income‑focused investors. However, regulatory headwinds in the banking sector and the recent exit from a U.S. leveraged finance line warrant monitoring.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near short‑term support
- bearish MACD bias
- increasing trading volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- valuation gap versus peers
- high dividend yield with low payout ratio
- strong cash position and low leverage
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- regulatory environment for regional banks
- sustainable dividend policy
- stable earnings outlook with forward upside
Key Metrics & Analysis
Financial Health
Revenue Growth-3.20%
Profit Margin30.37%
P/E Ratio13.9
ROE9.26%
ROA0.73%
P/B Ratio1.2
Op. Cash Flow€-783000000
Industry P/E17.3
Technical Analysis
TrendNeutral
RSI47.3
Support€14.73
Resistance€17.14
MA 20€16.12
MA 50€16.57
MA 200€14.33
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91
Valuation
Target Price€18.01
Upside/Downside12.65%
GradeUndervalued
TypeValue
Dividend Yield5.91%
Risk Assessment
Beta0.46
Volatility37.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.